[Evidenced-based medicine and future direction of Taxol].
Taxol was introduced for the clinical treatment of several solid tumor malignancies in the 1990s. It has been established that primary chemotherapy based on Taxol is the standard for non-small cell lung cancer and epithelial ovarian cancer. After initial chemotherapy containing doxorubicin, sequential administration of Taxol for advanced or metastatic breast cancer is recommended by the Food and Drug Administration in the United States. Taxol-based chemotherapy and/or concurrent chemoradiation for head and neck cancer, esophageal carcinoma, urothelial and prostate cancer are under investigation, but these trials have not produced evidence showing that they are superior to the present standard treatment for these malignancies. Although phase I/II trials of Taxol combined with new agents such as vinorelbine, topotecan, CPT-11 and others may demonstrate efficacy to a certain extent for some solid tumor malignancies, a phase III study will be required in the next stage. Taxol combined with other agents focusing on molecular targets will be an important approach in next decade. Inhibition of signal transduction by a noncytotoxic agent such as herceptine has the potential to enhance the cytotoxic effect of Taxo.
Hatae
M
M
Dept. of Obstetrics and Gynecology, Kagoshima City Hospital.
Nakamura
T
T
Ohnishi
Y
Y
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D018572:Disease-Free Survival; D019317:Evidence-Based Medicine; D005260:Female; D005544:Forecasting; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D010051:Ovarian Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000627:therapeutic use*; D015398:Signal Transduction
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel